NASDAQ · LGND
Healthcare · Biotechnology
$276.98
Up+$0.16 (+0.06%)
Updated Sep 16, 2026, 2:13 PM
SID Score
5.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LGND closed at $276.98 after 20 trading sessions, down 3.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $280.53 | $280.53 | $270.77 | $276.98 | 180.23K |
| Sep 14, 2026 | $284.93 | $287.14 | $280.12 | $280.65 | 158.77K |
| Sep 11, 2026 | $291.48 | $294.00 | $283.77 | $284.47 | 261.17K |
| Sep 10, 2026 | $285.00 | $291.26 | $283.04 | $289.25 | 146.55K |
| Sep 9, 2026 | $288.03 | $291.82 | $285.48 | $288.05 | 309.96K |
| Sep 8, 2026 | $285.05 | $289.28 | $278.3953 | $288.83 | 216.42K |
| Sep 4, 2026 | $287.41 | $290.00 | $285.47 | $285.60 | 132.39K |
| Sep 3, 2026 | $286.92 | $290.085 | $281.88 | $289.74 | 190.73K |
| Sep 2, 2026 | $285.73 | $290.33 | $281.69 | $286.92 | 189.62K |
| Sep 1, 2026 | $286.28 | $290.4063 | $281.99 | $284.27 | 185.02K |
| Aug 31, 2026 | $276.77 | $285.90 | $275.60 | $284.10 | 203.7K |
| Aug 28, 2026 | $283.70 | $283.995 | $277.36 | $280.49 | 127.7K |
| Aug 27, 2026 | $284.71 | $289.20 | $282.3975 | $284.52 | 206.33K |
| Aug 26, 2026 | $281.72 | $289.66 | $277.0074 | $287.85 | 147.46K |
| Aug 25, 2026 | $284.22 | $287.90 | $278.28 | $281.72 | 197.41K |
| Aug 24, 2026 | $286.27 | $286.27 | $279.87 | $280.18 | 158.24K |
| Aug 21, 2026 | $288.09 | $289.98 | $285.21 | $286.29 | 152.54K |
| Aug 20, 2026 | $289.11 | $293.37 | $284.87 | $287.39 | 138.95K |
| Aug 19, 2026 | $291.02 | $294.605 | $282.25 | $290.71 | 231.2K |
| Aug 18, 2026 | $291.00 | $293.51 | $284.41 | $287.59 | 247.48K |
The latest Smart Investors Daily articles mentioning LGND.
LGND research
Company profile and research snapshot.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Leerink Partners | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Jul 21, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
Benzinga · Sep 2, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a market
Yahoo · Aug 26, 2026
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.H.C. Wainwright
Benzinga · Aug 21, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals has a market
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LGND.
